Aids Weekly Plus
Healio reported on a study of the response of hemodialysis patients with chronic kidney disease to hepatitis B virus (HBV) vaccine. Researchers studied 83 hemodialysis patients being treated at clinics in southeastern Brazil in 2009 and 2010. The patients began hemodialysis 30 days after completing HBV vaccines, which they received according to National Immunization Program recommendations. Researchers categorized participants based on age; cause of renal disease; smoking or nonsmoking; and presence or absence of comorbidities such as diabetes or hypertension.
One month after the participants completed the vaccination schedule, researchers began examining their blood for antibodies and continued the testing every two months for a year. Of the participants, researchers categorized 41 percent as nonresponders with low antibody titers; 21.7 percent as poor responders; and 37.3 percent as good responders.
Researchers found that patients with diabetes or hypertension had a poorer response to the HBV vaccine. All participants had a decrease in antibody titers during the observation period, and 11.1 percent of poor responders had no antibodies against HBV during the 6-month follow-up. The researchers concluded that different HBV vaccine protocols should be used for this type of patient, and suggested annual blood tests for good responders and booster vaccines for poor and nonresponders.
The full report, “Hemodialysis and Hepatitis B Vaccination: A Challenge to Physicians,” was published in the International Journal of General Medicine (2014; 7:109–114).